Assessment of interleukin 17 and transforming growth factor-beta 1 in hepatitis C patients with disease progression
https://doi.org/10.47665/tb.37.4.1093
- Author:
Elbanan, W.K.
1
;
Fathy, S.A.
1
;
Ibrahim, R.A.
2
;
Hegazy, M.G.A.
1
Author Information
1. Biochemistry Department, Faculty of Science, Ain Shams University, Abbassia, 11566, Cairo, Egypt
2. Hepatology and Gastroenterology Department, Theador Bilharz Research institute, 12411, Giza, Egypt
- Publication Type:Journal Article
- From:Tropical Biomedicine
2020;37(No.4):1093-1104
- CountryMalaysia
- Language:English
-
Abstract:
Hepatitis C virus (HCV) infection in Egypt is the most serious health problem.
Identifying HCV-positive persons at high risk of early complications can help prioritize treatment
decisions. Recently, attention has been directed to non-invasive, accurate alternatives using
serum biochemical markers. The transforming growth factor β 1/interleukins pathway plays
an important role in the process of cell injury and inflammation. Thus, TGF-β1 and IL-17 were
assessed in serum of chronic HCV patients with correlation to hepatic inflammatory and
fibrotic status. The quantitative serum levels of TGF-β1 and IL-17 were analyzed among
chronic hepatitis C (CHC) patients (n=75) and normal control (NC) subjects (n=15). Disease
severity in patients was assessed using the Child-Pugh scores and METAVIR. Serum levels of
TGF-β1 and IL-17 were significantly increased in HCV patients compared to control group.
Furthermore, the levels of TGF-β1 and Il-17 were positively correlated to serum transaminases
and alpha-fetoprotein and they were negatively correlated with serum albumin and platelets.
Additionally, the serum levels of TGF-β1 and Il-17 were associated with inflammation grades
and stages of liver fibrosis. TGF-β1 and IL-17 may be hopeful serum biomarkers concerned in
the progression of liver inflammation and fibrosis accompanying chronic HCV infection.
Therefore, they could be used in the future as targets for anti-fibrotic therapy of chronic HCV
to ameliorate the disease progress.
- Full text:8.2020my1193.pdf
